Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. develops and commercializes medical devices for pediatric orthopedics, with products used in trauma and deformity, scoliosis, sports medicine and related procedures. Company news commonly covers quarterly financial results, revenue by product category, domestic and international sales trends, cash-flow metrics and updates to financial guidance.
Recurring product and market updates include specialty bracing, spine and deformity correction systems, implants, instruments and enabling technologies for pediatric care. Announcements also include investor conference participation and portfolio additions such as hospital-based traction systems and other products aimed at children with orthopedic conditions.
OrthoPediatrics (NASDAQ: KIDS) has successfully completed the first U.S. surgical procedures using its VerteGlide Spinal Growth Guidance System, a breakthrough treatment for Early Onset Scoliosis (EOS). The procedures were performed by Dr. Richard McCarthy and Dr. Kent Walker in Louisville, Kentucky.
The VerteGlide system, part of OrthoPediatrics' Scoliosis product suite, represents an innovative solution for complex spinal pathology in early onset scoliosis patients. The technology, which utilizes Shilla™ technology licensed from Medtronic, will be featured at the 60th Annual Meeting of the Scoliosis Research Society and the 19th International Congress on Early Onset Scoliosis later this year.
OrthoPediatrics (NASDAQ: KIDS) has announced a new distribution partnership with MY01 Inc. to expand access to MY01's Continuous Perfusion Sensing Technology (CPST) Platform for children and adolescents. The partnership focuses on addressing acute compartment syndrome, a time-sensitive emergency condition that particularly affects children with orthopedic traumatic injuries.
The collaboration combines MY01's innovative technology with OrthoPediatrics' dedicated pediatric sales force and medical education resources. This partnership aims to provide clinicians with better tools and training for diagnosing and treating compartment syndrome in pediatric patients, who often struggle to communicate symptoms effectively.
OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, has appointed Kelly Fischer to its Board of Directors effective August 8, 2025. Fischer, currently serving as Senior Vice President and CFO of Cook Medical, brings over two decades of financial and operational experience in the medical device industry.
The appointment coincides with the retirement of Terry Schlotterback, who served the company for over fifteen years as Director and Chairman of the Board. Fischer, with her background as an Audit Manager at Ernst & Young and her leadership at Cook Medical, aims to support OrthoPediatrics' strategy of market expansion and technology advancement in pediatric orthopedic care.
OrthoPediatrics (NASDAQ:KIDS) reported strong Q2 2025 financial results, achieving a record-breaking quarterly revenue of $61.1 million, up 16% year-over-year. The company demonstrated robust growth with domestic revenue increasing 17% and international revenue rising 12%. Adjusted EBITDA grew significantly by 58% to $4.1 million.
Key performance highlights include worldwide Trauma & Deformity revenue growth of 10% and Scoliosis revenue surge of 35%. The company expanded its Specialty Bracing Division with new clinics and entered Ireland, marking its first international operation. OrthoPediatrics has increased its full-year 2025 revenue guidance to $237.0-$242.0 million, projecting 16-18% growth, and expects to achieve positive free cash flow by Q4 2025.
OrthoPediatrics (NASDAQ: KIDS) announced significant expansion of its Specialty Bracing (OPSB) division through multiple new clinics and territory entries. The company has established its first California clinic in Los Angeles, opened a new facility in Dayton Children's Hospital, and expanded into the Denver, Colorado territory.
Through Acquihire opportunities, OPSB added multiple locations in New York City within major Children's Hospital centers and entered its first international market in Ireland. The Irish expansion complements OrthoPediatrics' existing implant business presence and creates opportunities for further European expansion.
OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, announced its participation in the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston, MA. The company's leadership, including CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat on Wednesday, August 13, 2025, at 11:00 am ET.
Investors can access the audio webcast through OrthoPediatrics' investor relations website, with a replay available after the event.
OrthoPediatrics (NASDAQ: KIDS) has launched its new 3P™ Pediatric Plating Platform™ Hip System in the United States, successfully completing its first surgical case. The innovative system is designed to treat proximal femur fractures and deformities in pediatric patients.
The comprehensive system features a Beam Screw construct and Locking Proximal Femur Plates available in Infant, Child, and Adolescent sizes. As part of the Trauma & Deformity Correction product suite, it integrates advanced implant and instrument technology for both trauma and deformity surgeries. Following the launch, more than 10 cases have been booked for August, with expected growth in procedural volume.
OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, has scheduled its second quarter 2025 financial results release for August 5, 2025 after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access both the live event and archived webcast through the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast recording will remain available for at least 90 days following the event.
OrthoPediatrics (NASDAQ: KIDS) has announced a major milestone in its Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study, with over 600 implants now being monitored across more than 300 pediatric patients.
The multi-center, post-market, prospective clinical follow-up study, launched in 2023, now includes 13 active sites across Canada, the United States, Australia, New Zealand, and South Africa. The study encompasses 17 different implant types and aims to assess the safety and efficacy of OrthoPediatrics' implant devices, focusing on implant survival and identifying device-related adverse events.
OrthoPediatrics (NASDAQ: KIDS) announced its continued role as the exclusive Emerald Sponsor for the 2025 Pediatric Orthopaedic Society of North America (POSNA) annual meeting. The company will showcase its expanding pediatric-specific solutions, including OrthoPediatrics Specialty Bracing and Enabling Technologies, across three exhibit booths. As part of its long-term commitment to POSNA, OrthoPediatrics provides support through specialty symposiums, educational grants, and scholarships for attendees.